Alagha Emily Couvillon, Fugh-Berman Adriane
Dahlgren Memorial Library, Georgetown University Medical Center, 3910 Reservoir Rd NW, Washington, DC, 20007, USA.
Department of Pharmacology and Physiology, and Department of Family Medicine, Georgetown University Medical Center, 3900 Reservoir Rd NW, Med-Dent SE402, Washington, DC, 20007, USA.
J Pharm Policy Pract. 2022 Nov 7;15(1):78. doi: 10.1186/s40545-022-00479-z.
Branded drug samples are one of the most important promotional tools that pharmaceutical manufactures employ. Pharmaceutical sales representatives ("drug reps") use samples to gain access to physicians and other prescribers. Sample provision is closely intertwined with visits by drug reps; detailing visits convince physicians to try new products, while sampling maintains the flow of prescriptions. Only drugs with the highest profit margins are sampled. Although physicians believe that samples save patients money, patients who receive samples have higher overall out-of-pocket costs. Most studies have found that patients in financial need are least likely to receive samples. Pharmaceutical marketers pitch samples as a low-risk way to deal with diagnostic uncertainty. In fact, there is no evidence that samples aid diagnosis. Sample availability may compromise patient safety by reducing compliance with guidelines and steering patients towards newer drugs, for which adverse effects have not been well-delineated. Although physicians believe that samples improve adherence for low-income patients, branded samples do not improve access or adherence Samples are not a charitable activity, but are instead a highly effective form of drug marketing. Sampling of branded drugs increase drug costs for everyone. Only a cohesive effort by clinicians, legislators and policymakers can end this practice. Evidence supports a ban on sample distribution of branded products.
品牌药样品是制药企业使用的最重要的促销工具之一。药品销售代表(“药代”)利用样品接触医生和其他开处方者。提供样品与药代的拜访紧密相连;详细介绍拜访说服医生试用新产品,而提供样品则维持处方的开具量。只有利润率最高的药品才会被用作样品。尽管医生认为样品能为患者省钱,但接受样品的患者总体自付费用更高。大多数研究发现,有经济需求的患者最不可能收到样品。药品营销人员将样品宣传为应对诊断不确定性的低风险方式。事实上,没有证据表明样品有助于诊断。样品的可得性可能会降低对指南的依从性,并引导患者使用不良反应尚未明确的新药,从而危及患者安全。尽管医生认为样品能提高低收入患者的依从性,但品牌药样品并不能改善可及性或依从性。提供样品并非慈善活动,而是一种非常有效的药品营销形式。品牌药的样品发放增加了所有人的药品成本。只有临床医生、立法者和政策制定者共同努力,才能终止这种做法。有证据支持禁止发放品牌产品的样品。